2 weeks Ago By Defense World Staff
Aileron Therapeutics ( NASDAQ:ALRN – Get Free Report ) and Tharimmune ( NASDAQ:THAR – Get Free Report ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Earnings and Valuation This table compares Aileron Therapeutics and Tharimmune”s gross revenue, earnings per share and valuation. Insider and Institutional Ownership Analyst Ratings This is a summary of current ratings and price targets for Aileron Therapeutics and Tharimmune, as reported by MarketBeat.
Aileron Therapeutics presently has a consensus target price of $19.00, indicating a potential upside of 420.55%.
Given Aileron Therapeutics’ higher probable upside, analysts clearly believe Aileron Therapeutics is more favorable than Tharimmune. Profitability This table compares Aileron Therapeutics and Tharimmune’s net margins, return on equity and return on assets. Volatility & Risk Aileron Therapeutics has a beta of 2.
33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500.
Summary Aileron Therapeutics beats Tharimmune on 8 of the 9 factors compared between the two stocks. About Aileron Therapeutics ( Get Free Report ) Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States.
The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications.
The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007.
Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas. About Tharimmune ( Get Free Report ) Tharimmune, Inc.
, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc.
for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc.
and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc.
was incorporated in 2017 and is headquartered in Bridgewater, New Jersey. Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
